Evaluation of preoperative predictive values of serum CA15-3 and CEA within Sudanese women with breast cancer. by Ahmed, HG & Hussein, MOM
© Sudan JMS Vol. 4, No. 1, Mar.2009                   71
bÜ|z|ÇtÄ TÜà|vÄx
Evaluation of Preoperative Predictive Values of Serum CA15-3 and CEA within 
Sudanese Women with Breast Cancer.
Hussain Gadelkarim Ahmed and Mohammed Omer M Hussein
Abstract
Objectives: Early detection of cancer comprises early diagnosis in symptomatic 
and screening of asymptomatic individuals. Our aim was to evaluate the 
significant values of carbohydrate antigen 15-3 (CA15-3) and/or 
Carcinoembryonic antigen (CEA) in women with breast cancer.
Design and setting: This case control study was conducted in Khartoum 
Teaching Hospital, Khartoum, Sudan. 
Application of such measurement may be helpful within screening and early 
detection efforts in such a country like Sudan with poor resources.
Methods: We examined by serological radioimmuno-assay methods, significant elevation of 
CA15-3 and CEA serum samples obtained from 100  women  of whom 40% and 35% were patients 
with histopathologically confirmed breast cancer and benign breast lumps respectively and the 
remaining 25% were apparently healthy controls.
Statistical analysis: Data were analyzed by using a computer SPSS program. 
Results: Among the 75 patients with breast lumps, 33 (44%) and 31(37.3%) showed high CA15-3 
and CEA levels respectively. Of the 40 carcinomas, high expressions of CA15-3 and CEA were 
found among 28(70%) and 24(60%) respectively. Notably, only 2(8%) of the controls showed 
lightly elevated CEA.
Conclusions: The obtained Specificity of 85.7%, 80% and sensitivity of 70%, 60% for CA15-3 and 
CEA correspondingly, support the combined application of both markers in screening for breast 
cancer.
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emale breast cancer is by far the 
leading cancer in the Sudan
1
. The 
alarmingly high frequency of women 
presenting with advanced breast cancer to the 
Radiation Isotope Center Khartoum (RICK) 
and Gaziera Institute for Cancer treatment 
and Molecular Biology (GICMB), which are  
the only two oncology centers in the Sudan, 
has prompted looking for an investigation 
that might help in solving this real health 
problem. However, there were variations in 
the proportions of breast cancer, during the 
period 1990-2001, as shown in table1.
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The highest percentages were recorded in 
1998 (38.4% of all female cancers), followed 
by the years, 2000, 1999 and 2001, which 
attended 36.03%, 35.2% and 32.4% 
respectively
1
. Furthermore, the records from 
GICMB, indicated the highest percentages 
(42%) of breast cancer
2
. 
CA 15-3 and CEA have been most widely 
used as serum tumor markers in follow-up 
and detection of breast cancer recurrence. In 
this study we have specifically focused upon 
the diagnostic implications and utility of 
preoperative CA 15-3 and CEA levels.  
The incidence and mortality of breast cancer 
are high in the Sudan, and the frequency is 
increasing particularly amongst younger 
women
3
. This might not be entirely due to an 
increase in the at risk population, but may be 
due to a lower threshold and better 
recognition of new cases.
F
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Table.1: Frequencies of breast cancer from 1990 – 2001 (RICK 2002).
Year Breast Cancer Percentage Female Cancers
1990 200 21.3 % 941
1991 140 15.7 % 890
1992 327 26.1 % 1255
1993 162 11.1 % 1462
1994 255 27.3 % 934
1995 60 5.9 % 1018
1996 314 28.4 % 1106
1997 349 29 % 1203
1998 502 38.4 % 1306
1999 455 35.2 % 1293
2000 481 36.03 % 1335
2001 531 32.4 % 1639
Therefore, the assessment of the value of 
circulating tumor markers (CA15-3& CEA) 
for screening and preoperative predicting of 
breast cancer is very important.
High levels of CA15-3, during the post-
therapeutic follow-up of a cancer of the 
breast indicated recurrence or metastasis in 
75 to 90% of the cases
4-6
. A significant 
positive association was found between CA 
15-3 concentrations and both tumor stage and 




Preoperative serum concentrations of CA15-
3 appear to have a significant relation to 
outcome in patients with early breast 
carcinoma and may have a role in the rational 




A combination of CEA and CA15-3 has been 
reported to improve lead detection time in 





In this study we evaluated the role of serum 
CA15-3 and CEA as compared to 
histopathology in the investigation and 
screening for breast cancer within women 
with palpable breast lumps. 
One hundred subjects were randomly 
selected for this study.  Of  whom 75  were 
patients with breast masses and 25 were 
apparently healthy controls. All studied 
subjects were females their ages ranging 
between 20- 75 years with a mean age of 42 
years. Brief clinical and personal data were 
obtained from each patient during the 
interview and reviewing of the ethical 
consent.
Serum obtained from blood specimens was 
analyzed using radio- immuno assay for 
breast tumor markers using antiserum to CA-
15-3 and CEA.
The CA15-3 or CEA assay is a two-step 
"sandwich" type assay in which two 
monoclonal mouse antibodies, directed 
against two different epitopes of the 
molecule, are employed. 
Samples or standards were incubated in tubes 
coated with the monoclonal antibody, the 
contents of the tubes were then aspirated and 
the presence of CA15-3 or CEA in the 
sample was revealed by incubation with a 
second, 
125
1-labeled monoclonal antibody. 
The contents of the tubes were aspirated after 
this second incubation and unbound labeled 
antibody was eliminated by washing. 
The amount of bound reactivity measured in 
a gamma counter was proportional to the 
CA15-3 or CEA concentration. 
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CA15-3 or CEA assayed adopting the 
following steps: Number a duplicate series of 
anti-CA15-3, or CEA-coated tubes.
First incubation: a) Add 200 µl of standard or 
sample, control, prepared in to tubes 
prepared for the assay.b) Shake gently. c) 
Cover tubes.d) Incubate tubes for 2 hours at 
room temperature (18-25˚C) with continuous 
horizontal shaking (400rpm).
Washing: a. Aspirate carefully the contents 
of the tubes. b. Add 2 ml of distilled water 
to each and immediately aspirate carefully 
contents of the tubes. Wash once more. No 
liquid should remain in tubes.
Second incubation: a. Add 200 µl of tracer 
to tubes. b. Add 200 µl of tracer to 2 
additional tubes to obtain total counts T.
c. Cover tubes.
d. Incubate tubes for 1 hour at room 
temperature (18-25˚C) with  continuous 
horizontal shaking (400 rpm).
Washing:
a. Aspirate carefully the contents of 
the tubes (except of tubes T).
            B. Rinse tubes (except tubes T) with 
2 ml of distilled water and immediately 
aspirate carefully contents of the tubes. Wash 
once more. No trace of the dye should remain 
in the tubes.
Determine the radioactivity of the tubes in 
order to obtain bound (B) and total cpm (T).
Sample processing for histopathology
Biopsies of thickness of 10-mm in diameter 
were selected from tissues required for 
histopathology. These biopsies were fixed in 
neutral buffered formalin for 30 hours, and 
then processed in tissue processing machine 
using; Neutral buffered formalin for 30 
minutes followed by ascending alcoholic 
concentrations70%, 90%, 3 changes of 
absolute ethanol one hour for each. The 
tissues were then placed in 2 changes of 
xylene 2 hours for each then transformed into 
2 changes of molting paraffin wax for more 
than 4 hours.  
Five sections of 5µm in thickness were 
obtained from formalin-fixed paraffin wax 
embedded tissues using a rotary microtome. 
Sections were stained using haematoxylin 




A total of 75 women who presented to 
Khartoum Teaching Hospital with palpable 
breast masses, in addition to 25 apparently 
healthy subjects (controls) were studied. 
Their ages ranged from 20 to 75 years 
(mean=42). 
As the histopathology is a gold standard, 
biopsies from the 75 patients with breast 
palpable lumps were investigated 
histopathologically. Breast cancer was 
detected among 40(53.3%). Within these 40 
patients, high levels CA15-3 and CEA were 
determined in 28(70%) and 24(60%) 
respectively. Of the remaining 35(46.7%) 
patients with benign breast lumps, elevated 
levels of CA15-3 and CEA were detected 
among, 5(14.3%) and 7(20 %) 
correspondingly as shown in tables 2, 3.
Table 2:  Description of CA15-3 versus histopathology results.
                           CA15-3
Positive Negative Total
Histopathology N % N % N %
Positive 28 37.3 12 16 40 53.3
 Negative   5 6.7 30 40 35 46.7
Total 33 44 42 56 75 100
P < 0.001
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Table 3. Description of CEA versus histopathology results according.
CEA
Positive Negative Total
Histopathology N % N % N %
Positive 24 32 16 21.3 40 53.3
Negative 7 9.3 28 37.4 35 46.7
Total 31 41.3 44 58.7 75 100
P < 0.05
Although, 12 ( 30%) of the patients that were 
histopathologically proved as having breast 
cancer were found with low (negative) levels 
of CA15-3, as well as 5 (14%) patients with 
those  expected to reveal low levels 
(negative) have revealed higher levels, these 
findings showed a significant role for CA15-
3 as a predictor for breast cancer ( P< 0.001), 
as indicated in table.2. 
Additionally, though 40% of patients with 
breast cancer were having low levels of CEA 
(negative) and  20% of those patients with 
benign breast lumps revealed elevated levels 
of CEA (positive), but also CEA have shown 
statistically significant important( P< 0.05) as 
shown in table.3.
Thereafter, specificity of 85.7% and 80% as 
well as a sensitivity of 70% and 60%, as well 
as positive predictive values of 85% and 
77.4% was credited for CA15-3 and CEA 
respectively. Additionally, negative 
predicative value 71.4% was determined for 
CA15-3, hence, 63.6% was obtained by 
CEA.
When comparing the results obtained by the 
two markers; they agreed in 21(28%) 
positive and 32(42.7%) negative results. 
Nonetheless, 10(13.3%) were detected 
positive by CEA and negative by CA15-3, on 
the other side, 12 (16%) were Negative by 
CEA and turned to be positive by CA15-3. 
Concerning the 25 apparently healthy 
controls, only 2 subjects among the controls 
showed slightly elevated CEA levels.
The description of both markers findings 
versus histopathology is shown in table.4
Table 4. Description of CA15-3 and CEA findings versus histopathology results.
                                                                     CA15-3 and CEA
Positive Negative Total
Histopathlogy N % N % N %
Positive 31 77.5 9 22.5 40 100
Negative 12 34.2 23 65.8 35 100
Total 43 57.3 32 42.7 75 100
31 (77.5%) of patients with positivity of both 
markers turned to be positive by 
histopathology, notably, 12(34.2%) of those 
considered as no-cancer patients by 
histopathology have scored high levels of 
both markers. These findings exposed 
specificity of 65.7% sensitivity of 77.5%, in 
addition to positive and negative predictive 
values of 72% and 71.8% correspondingly.
Discussion
Breast cancer remains the most common 
cancer in women (excluding skin cancer)
14
. 
Mortality rates have begun to decrease in the 
past decade, most likely because of better 
treatments, earlier detection, and improved 
screening methods.  However, the objective 
of this study was to evaluate the reliability of 
circulating tumor markers (CA15-3 & CEA) 
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in screening for breast cancer, using 
histopathology as gold standard. 
CA15-3 
Our findings in this study give a considerable 
importance for CA15-3 as, a marker that can 
predict breast cancer (P< 0.001), with high 
specificity 83.3% and sensitivity of 70%. 
These findings supported many studies that 
denoted the reliability of CA15-3 in detection 
of breast cancer. A significant positive 
association between CA15-3 concentrations 
and tumor stage was reported
8,15,16
. 
Preoperative serum concentrations of CA 15-
3 appeared to have a significant relation to 
outcome in patients with early breast 
carcinoma.  
CA 15.3 has a higher sensitivity in early 
diagnosis of relapse, as well as being a useful 
tool for the early diagnosis of metastases, as 
it is the first indicator of recurrence in 69.5% 
of patients with relapse (76.3% in patients 
with metastases)
17
. Furthermore, an initially 
elevated CA 15-3 level is associated with a 




As indicated in the results, 12(30%) of the 
cancer cases showed low levels of CA15-3, 
also, 5 (14.3%) of those with benign diseases 
revealed elevated CA15-3 levels as indicated 
in Table.2. However, these discrepancies 
were expected as there are several abnormal 
conditions, other than breast cancer that may 




CEA is produced by breast cancer tissue and 
is then secreted in blood and various body 
fluids. Breast adenocarcinoma sections 
stained with monoclonal anti-CEA antibody, 
exhibited increased CEA production, which 
is reflected by elevated serum CEA levels
9
.   
In this study, CEA, scored considerable 
measures in tern of specificity (80%) and 
sensitivity (60%), in addition to positive and 
negative predictive values of 77.4%and 63.6 
respectively.  These findings exposed a 
reasonable evidence for the application of 
CEA as a marker that can predict breast 
cancer and this was also found to be 
statistically significant (P< 0.05). However, 
many studies have reported various 
specificities, sensitivities and predictive 
values for CEA. Omar et al.
21
reported 66% 
sensitivity and 93% specificity with CEA as 
a diagnostic test for malignancy of breast, 
whereas, AI Jarallah et al
22
. found a 
sensitivity of 70% and positive predictive 
value of 91%. Naghshvar, et al.
23
 reported 
sensitivity and specificity of CEA are 48% 
and 83%, respectively. These variations may 
be attributed to the tumor stage and status.
 This marker failed to detect 16(40%) of the 
positive cases, and was elevated in 7(20%) of 
those with benign diseases and in 2(40%) of 
the apparently healthy controls. These results 
were expected, since elevated CEA levels 
can occur in patients with a number of 
benign diseases, such as cirrhosis, pulmonary 
emphysema, rectal polyps, benign breast 
disease and ulcerative colitis
18
.
Regarding, the disagreement between the 
CEA and histopathology in 16 (40%) cases -
negative by CEA and confirmed to be 
positive by histopathology-, the low 




The two controls with high CEA levels were 




It is accepted that assays detecting the CA15-
3 are more sensitive than those detecting 
CEA and are more often used in diagnosing 
this disease, but the combined use of the two 
types of assays can be more effective
11, 12
. 
However, specificity of 85.7% and 80% as 
well as a sensitivity of 70% and 60%, as well 
as positive predictive values of 85% and 
77.4% were credited for CA15-3 and CEA 
respectively. Likewise, negative predicative 
value of 71.4% and 63.6% was obtained by 
CA15-3 CEA. These findings proved that 
CA15-3 has better specificity and sensitivity 
than CEA. They also supported a number of 
studies, revealing that CA15-3 has superior 
sensitivity compared with CEA, and are more 
often expressed in breast cancer, but the 
combined use of the two types of assays can 
be more effective
17,25,26
. This is strongly 
supported by our findings.
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  Moreover, CA 15-3 is one of the first 
circulating prognostic factors for breast 
cancer. Preoperative concentrations thus 
might be combined with other existing 
prognostic factors for predicting outcome in 
patients with newly diagnosed breast cancer
10
. 
A combination of CEA and CA15-3 has been 
reported to improve lead detection time in 





 In conclusion; the combined use of 
circulating tumor marker (CA15-   &CEA) 
can emerge as a reliable screening test for 
breast cancer.
  Performing circulating tumor markers 
(CA15-3 & CEA) is less invasive procedure 
and is relatively cheap, therefore might be 
appropriate within a breast-screening 
program in developing countries.
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